Based on the subtype of the clinical tumor, primary treatments comprised endocrine therapy, anti-HER2 targeted therapy, and chemotherapy.[19] By the end of 2006, landmark trial results demonstrated that chemotherapy coupled with curative HER2-targeting agent trastuzumab significantly benefits progression-free survival and overall OS in patients with early- and late- stages HER2-positive breast cancer.[4]. The gene discussed is ERBB2; the disease is neoplasm.